Dermira (NASDAQ:DERM) has been assigned a $45.00 target price by stock analysts at Cantor Fitzgerald in a research note issued on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 87.11% from the stock’s current price.

DERM has been the subject of a number of other reports. Zacks Investment Research raised shares of Dermira from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. BidaskClub cut shares of Dermira from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Needham & Company LLC reissued a “buy” rating and set a $46.00 price target on shares of Dermira in a research report on Sunday, September 17th. Mizuho reissued a “buy” rating and set a $43.00 price target (up from $40.00) on shares of Dermira in a research report on Thursday, September 7th. Finally, Leerink Swann restated an “outperform” rating and set a $41.00 price objective (down from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. Five investment analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. Dermira currently has a consensus rating of “Hold” and an average target price of $43.33.

Dermira (NASDAQ:DERM) opened at $24.05 on Wednesday. Dermira has a 12-month low of $21.35 and a 12-month high of $38.75. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 1.40.

In other news, CEO Thomas G. Wiggans sold 9,500 shares of Dermira stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $27.51, for a total value of $261,345.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Eugene A. Bauer sold 7,500 shares of Dermira stock in a transaction that occurred on Wednesday, October 11th. The stock was sold at an average price of $30.04, for a total transaction of $225,300.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,800 shares of company stock valued at $808,267. 13.30% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its stake in shares of Dermira by 15.6% in the second quarter. BlackRock Inc. now owns 3,922,253 shares of the biopharmaceutical company’s stock worth $114,294,000 after acquiring an additional 529,405 shares during the period. Jennison Associates LLC grew its stake in shares of Dermira by 0.3% in the third quarter. Jennison Associates LLC now owns 2,640,740 shares of the biopharmaceutical company’s stock worth $71,300,000 after acquiring an additional 7,746 shares during the period. Vanguard Group Inc. grew its stake in shares of Dermira by 9.8% in the second quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock worth $40,735,000 after acquiring an additional 125,157 shares during the period. Voya Investment Management LLC grew its stake in shares of Dermira by 61.4% in the second quarter. Voya Investment Management LLC now owns 1,227,948 shares of the biopharmaceutical company’s stock worth $35,783,000 after acquiring an additional 467,356 shares during the period. Finally, State Street Corp grew its stake in shares of Dermira by 38.4% in the second quarter. State Street Corp now owns 821,748 shares of the biopharmaceutical company’s stock worth $23,946,000 after acquiring an additional 228,093 shares during the period. Hedge funds and other institutional investors own 99.48% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/30/dermira-derm-given-a-45-00-price-target-at-cantor-fitzgerald.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc and related companies with MarketBeat.com's FREE daily email newsletter.